Laboratorios Richmond SACIF
Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs … Read more
Laboratorios Richmond SACIF (RICH) - Net Assets
Latest net assets as of September 2025: AR$72.73 Billion ARS
Based on the latest financial reports, Laboratorios Richmond SACIF (RICH) has net assets worth AR$72.73 Billion ARS as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AR$354.98 Billion) and total liabilities (AR$282.24 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AR$72.73 Billion |
| % of Total Assets | 20.49% |
| Annual Growth Rate | 65.24% |
| 5-Year Change | 1833.11% |
| 10-Year Change | 67886.05% |
| Growth Volatility | 96.4 |
Laboratorios Richmond SACIF - Net Assets Trend (2006–2024)
This chart illustrates how Laboratorios Richmond SACIF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Laboratorios Richmond SACIF (2006–2024)
The table below shows the annual net assets of Laboratorios Richmond SACIF from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | AR$65.35 Billion | +30.74% |
| 2023-12-31 | AR$49.98 Billion | +389.19% |
| 2022-12-31 | AR$10.22 Billion | +90.07% |
| 2021-12-31 | AR$5.38 Billion | +59.02% |
| 2020-12-31 | AR$3.38 Billion | +60.98% |
| 2019-12-31 | AR$2.10 Billion | +89.03% |
| 2018-12-31 | AR$1.11 Billion | +61.46% |
| 2017-12-31 | AR$688.05 Million | +263.17% |
| 2016-12-31 | AR$189.46 Million | +97.11% |
| 2015-12-31 | AR$96.12 Million | +3.34% |
| 2014-12-31 | AR$93.02 Million | +2.17% |
| 2013-12-31 | AR$91.04 Million | -1.06% |
| 2012-12-31 | AR$92.01 Million | +83.64% |
| 2011-12-31 | AR$50.10 Million | +11.80% |
| 2010-12-31 | AR$44.82 Million | -16.59% |
| 2009-12-31 | AR$53.73 Million | +83.44% |
| 2008-12-31 | AR$29.29 Million | +121.09% |
| 2007-12-31 | AR$13.25 Million | +71.04% |
| 2006-12-31 | AR$7.75 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Laboratorios Richmond SACIF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 209624.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | AR$15.58 Billion | 24.23% |
| Other Components | AR$48.72 Billion | 75.77% |
| Total Equity | AR$64.30 Billion | 100.00% |
Laboratorios Richmond SACIF Competitors by Market Cap
The table below lists competitors of Laboratorios Richmond SACIF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NEORIGIN Co. Ltd
KQ:094860
|
$25.00 Million |
|
H-FARM SPA
F:5JQ
|
$25.01 Million |
|
Maniker
KO:027740
|
$25.01 Million |
|
CTK Co. Ltd
KQ:260930
|
$25.01 Million |
|
NextCure Inc
NASDAQ:NXTC
|
$24.99 Million |
|
Kora Saude Participacoes SA
SA:KRSA3
|
$24.99 Million |
|
Edisun Power Europe AG
SW:ESUN
|
$24.98 Million |
|
Dorel Industries Inc
PINK:DIIBF
|
$24.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Laboratorios Richmond SACIF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 49,104,581,619 to 64,297,715,724, a change of 15,193,134,105 (30.9%).
- Net income of 23,845,088,195 contributed positively to equity growth.
- Other factors decreased equity by 8,651,954,090.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AR$23.85 Billion | +37.09% |
| Other Changes | AR$-8.65 Billion | -13.46% |
| Total Change | AR$- | 30.94% |
Book Value vs Market Value Analysis
This analysis compares Laboratorios Richmond SACIF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.30x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 215.36x to 2.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | AR$8.52 | AR$1835.00 | x |
| 2018-12-31 | AR$13.02 | AR$1835.00 | x |
| 2019-12-31 | AR$25.39 | AR$1835.00 | x |
| 2020-12-31 | AR$41.86 | AR$1835.00 | x |
| 2021-12-31 | AR$65.55 | AR$1835.00 | x |
| 2022-12-31 | AR$124.95 | AR$1835.00 | x |
| 2023-12-31 | AR$608.10 | AR$1835.00 | x |
| 2024-12-31 | AR$796.24 | AR$1835.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Laboratorios Richmond SACIF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 37.09%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 25.98%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 4.05x
- Recent ROE (37.09%) is above the historical average (8.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 10.26% | 1.31% | 0.84x | 9.38x | AR$147.11K |
| 2016 | 63.14% | 11.07% | 0.99x | 5.74x | AR$79.78 Million |
| 2017 | 5.92% | 4.15% | 0.63x | 2.26x | AR$-28.05 Million |
| 2018 | -20.51% | -11.87% | 0.67x | 2.57x | AR$-320.73 Million |
| 2019 | 5.68% | 2.99% | 0.76x | 2.50x | AR$-88.58 Million |
| 2020 | 14.38% | 7.87% | 0.76x | 2.41x | AR$148.19 Million |
| 2021 | 11.17% | 3.56% | 0.65x | 4.85x | AR$62.10 Million |
| 2022 | 1.62% | 0.88% | 0.45x | 4.04x | AR$-845.59 Million |
| 2023 | -48.12% | -27.80% | 0.25x | 6.87x | AR$-28.54 Billion |
| 2024 | 37.09% | 25.98% | 0.35x | 4.05x | AR$17.42 Billion |
Industry Comparison
This section compares Laboratorios Richmond SACIF's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $35,968,000
- Average return on equity (ROE) among peers: 11.40%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Laboratorios Richmond SACIF (RICH) | AR$72.73 Billion | 10.26% | 3.88x | $24.99 Million |
| Instituto Rosenbusch S.A. (ROSE) | $35.97 Million | 11.40% | 0.35x | $1.57 Million |